title: c-Met in chromophobe renal cell carcinoma.
abstract: c-Met plays a role as a prognostic marker in clear cell renal cell carcinoma. In addition, recently the tyrosine kinase inhibitor cabozantinib targeting c-Met was approved for the treatment of advanced renal cell carcinoma (RCC). In contrast to clear cell RCC, little is known about c-Met expression patterns in rarer RCC subtypes. The aim of this study was to evaluate the prevalence, distribution and prognostic impact of c-Met expression on chromophobe (ch)RCC. Patients who underwent renal surgery due to chRCC were retrospectively evaluated. Tumor specimens were analyzed for c-Met expression by immunohistochemistry. Expression data were associated with clinicopathological parameters including patient survival. Eighty-one chRCC patients were eligible for analysis. Twenty-four (29.6%) patients showed a high c-Met expression (c-Methigh, staining intensity higher than median). Our results showed an association between c-Methighexpression and the existence of lymph node metastasis (p = 0.007). No further significant clinicopathological associations with c-Met were identified, also regarding c-Met expression and overall survival. In conclusion, to our knowledge this is the first study evaluating the prognostic impact of c-Met in a considerably large cohort of chRCC. High c-Met expression is associated with the occurrence of lymph node metastasis. This indicates that c-Met might be implicated into metastatic progression in chRCC.
authors.affiliation: Institute of Pathology, Technical University Munich (TUM), Trogerstraße 18, 81675, Munich, Germany. f.erlmeier@tum.de.|German Renal Cell Tumor Consortium, Jena, Germany. f.erlmeier@tum.de.
authors.forename: Franziska
authors.initials: F
authors.lastname: Erlmeier
authors.affiliation: Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Ivanyi
authors.affiliation: German Renal Cell Tumor Consortium, Jena, Germany.|Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
authors.forename: Arndt
authors.initials: A
authors.lastname: Hartmann
authors.affiliation: Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Autenrieth
authors.affiliation: The Munich Cancer Registry of the Tumorzentrum Munich, Institute of Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.
authors.forename: Max
authors.initials: M
authors.lastname: Wiedemann
authors.affiliation: Institute of Pathology, Technical University Munich (TUM), Trogerstraße 18, 81675, Munich, Germany.|German Cancer Consortium (DKTK), Heidelberg, Germany.
authors.forename: Wilko
authors.initials: W
authors.lastname: Weichert
authors.affiliation: German Renal Cell Tumor Consortium, Jena, Germany.|Clinic for Urology, University Hospital Muenster, Muenster, Germany.
authors.forename: Sandra
authors.initials: S
authors.lastname: Steffens
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000201:enzymology* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000201:enzymology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D019859:Proto-Oncogene Proteins c-met / Q000096:biosynthesis*
chemical_list: D019859:Proto-Oncogene Proteins c-met
keywords: Chromophobe histology; Chromophobe subtype; Epithelial-mesenchymal transition; Renal cell carcinoma; Survival; c-Met